图书馆订阅: Guest
Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集
身体康复医学评论综述
SJR: 0.121 SNIP: 0.228 CiteScore™: 0.17

ISSN 打印: 0896-2960
ISSN 在线: 2162-6553

身体康复医学评论综述

DOI: 10.1615/CritRevPhysRehabilMed.2016018768
pages 85-93

Effect of Zoledronic Acid on Osteoporosis after Chronic Spinal Cord Injury: A Randomized Controlled Trial

Shiela Mary Varghese
Caritas Hospital, Kottayam, Kerala, India
Bobeena Chandy
Department of Physical Medicine and Rehabilitation, Christian Medical College Vellore, Tamil Nadu, India
Raji Thomas
Department of Physical Medicine and Rehabilitation, Christian Medical College, Vellore, Tamil Nadu, India, 632004
George Tharion
Department of Physical Medicine and Rehabilitation, Christian Medical College, Vellore, Tamil Nadu, India

ABSTRACT

This was a double-blind, randomized, placebo-controlled parallel-group pilot trial to observe the effect of single-dose zoledronic acid on bone mineral density (BMD) in persons with chronic spinal cord injury (SCI). Twenty-eight subjects with traumatic SCI, at least 1 year after trauma who had osteoporosis were randomized to receive either intervention or placebo. The intervention consisted of a single dose of intravenous zoledronic acid (Zoldonat) 4 mg in 100 ml of normal saline infused over 20 minutes. The placebo group received 100 ml of normal saline infusion. BMD of hip and forearm was measured by dual-energy x-ray absorptiometry (DEXA) at baseline and 1 year after intervention. A nonparametric test, the Wilcoxon signed-rank test, was used to evaluate the postintervention change in BMD. BMD of distal forearm showed a statistically significant rise in both groups after intervention (p = 0.004 in placebo group, p = 0.004 in zoledronic acid group). At 1 year, BMD of total hip in the placebo group showed a statistically significant reduction (p = 0.017), whereas that the zoledronic acid group did not show a statistically significant reduction (p = 0.082). BMD of femoral neck showed a statistically significant reduction in both groups (p = 0.002 in the placebo group; p = 0.044 in the zoledronic acid group). However, the magnitude of decrease was greater in placebo recipients. We conclude that a single dose of zoledronic acid partially prevents ongoing reduction in BMD at total hip but not at femoral neck in patients with chronic SCI.


Articles with similar content:

A Top-Down versus Bottom-Up Approach to Lower-Extremity Motor Recovery and Balance Following Acute Stroke: A Pilot Randomized Clinical Trial
Critical Reviews™ in Physical and Rehabilitation Medicine, Vol.31, 2019, issue 2
Abraham Joshua, Chakrapani M, Z. K. Misri, Vidyasagar Pagilla, Vijaya Kumar , Prasanna Mithra
Predictors of Left Ventricular Myocardial Structural Remodeling in Patients with Atrial Fibrillation
International Journal of Physiology and Pathophysiology, Vol.9, 2018, issue 3
E. Levchenko, Alexey Goryachyi, Anatoliy I. Gozhenko, Yuryi Karpenko
Effectiveness of the Dynamic Internal Fixator System in Metaphyseal and Epiphyseal Femoral Fractures: 10 Years of Experience and Future Expectations
Journal of Long-Term Effects of Medical Implants, Vol.29, 2019, issue 2
Francesco Saverio Sirabella, Andrea Angelini, Francesca Giovannini, Concetto Battiato, Pietro Ruggieri
A Phase I/II Study of Ling Zhi Mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) Extract in Patients with Coronary Heart Disease
International Journal of Medicinal Mushrooms, Vol.6, 2004, issue 4
Guoliang Chen, Jingxian Ye, Yihuai Gao, Shufeng Zhou, Xihu Dai
Kinematic and Kinetic Analysis of the Knee Joint before and after a PCL Retaining Total Knee Replacement during Gait and Single Step Ascent
Journal of Long-Term Effects of Medical Implants, Vol.21, 2011, issue 4
Nikolaos Darras, Dimitrios Mastrokalos, loannis V. Michos, Stergios N. Lallos, Nikolaos E. Efstathopoulos, Alexandros P. Apostolopoulos, Magda Tzomaki